MA69412B1 - Récepteurs antigéniques chimériques présentant une spécificité pour bcma et leurs utilisations - Google Patents

Récepteurs antigéniques chimériques présentant une spécificité pour bcma et leurs utilisations

Info

Publication number
MA69412B1
MA69412B1 MA69412A MA69412A MA69412B1 MA 69412 B1 MA69412 B1 MA 69412B1 MA 69412 A MA69412 A MA 69412A MA 69412 A MA69412 A MA 69412A MA 69412 B1 MA69412 B1 MA 69412B1
Authority
MA
Morocco
Prior art keywords
bcma
chimeric antigen
antigen receptors
cells expressing
engineered cells
Prior art date
Application number
MA69412A
Other languages
English (en)
Inventor
Jessica KIRSHNER
Frank DELFINO
David DILILLO
Olga SINESHCHEKOVA
Kevin BRAY
Thomas Craig MEAGHER
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of MA69412B1 publication Critical patent/MA69412B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'antigène de maturation des lymphocytes B (BCMA) est exprimé sur les plasmocytes malins. La présente invention concerne des récepteurs d'antigènes chimériques spécifiques du BCMA et des cellules exprimant de tels récepteurs d'antigènes chimériques. Dans certains modes de réalisation, des cellules modifiées exprimant les récepteurs d'antigènes chimériques de la présente invention sont capables d'inhiber la croissance des tumeurs exprimant BCMA. Ces cellules modifiées sont utiles pour le traitement de maladies et de troubles pour lesquels une réponse immunitaire ciblée sur BCMA, stimulée ou induite, est souhaitée et/ou bénéfique sur le plan thérapeutique. Par exemple, les cellules modifiées exprimant les récepteurs d'antigènes chimériques spécifiques du BCMA de l'invention sont utiles pour le traitement de divers cancers, dont le myélome multiple.
MA69412A 2018-07-19 2019-07-18 Récepteurs antigéniques chimériques présentant une spécificité pour bcma et leurs utilisations MA69412B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862700615P 2018-07-19 2018-07-19
EP23215003.7A EP4324851B1 (fr) 2018-07-19 2019-07-18 Récepteurs antigéniques chimériques présentant une spécificité pour bcma et leurs utilisations

Publications (1)

Publication Number Publication Date
MA69412B1 true MA69412B1 (fr) 2025-12-31

Family

ID=67515170

Family Applications (2)

Application Number Title Priority Date Filing Date
MA69412A MA69412B1 (fr) 2018-07-19 2019-07-18 Récepteurs antigéniques chimériques présentant une spécificité pour bcma et leurs utilisations
MA65527A MA65527B1 (fr) 2018-07-19 2019-07-18 Récepteurs antigéniques chimériques possédant une spécificité pour le bcma, et utilisations correspondantes

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA65527A MA65527B1 (fr) 2018-07-19 2019-07-18 Récepteurs antigéniques chimériques possédant une spécificité pour le bcma, et utilisations correspondantes

Country Status (31)

Country Link
US (2) US12150959B2 (fr)
EP (2) EP3823665B1 (fr)
JP (2) JP7404335B2 (fr)
KR (1) KR102901020B1 (fr)
CN (2) CN112437671B (fr)
AU (2) AU2019308290B2 (fr)
BR (1) BR112021000919A2 (fr)
CA (1) CA3106612A1 (fr)
CL (2) CL2021000142A1 (fr)
CO (1) CO2021000334A2 (fr)
DK (2) DK4324851T3 (fr)
EA (1) EA202190315A1 (fr)
ES (2) ES3042810T3 (fr)
FI (2) FI4324851T3 (fr)
HR (2) HRP20240494T1 (fr)
HU (2) HUE066474T2 (fr)
IL (1) IL279979A (fr)
LT (2) LT4324851T (fr)
MA (2) MA69412B1 (fr)
MD (2) MD4324851T2 (fr)
MX (3) MX2021000532A (fr)
MY (1) MY207197A (fr)
PH (1) PH12021550036A1 (fr)
PL (2) PL4324851T3 (fr)
PT (2) PT3823665T (fr)
RS (2) RS65384B1 (fr)
SG (1) SG11202100221VA (fr)
SI (2) SI3823665T1 (fr)
SM (2) SMT202400102T1 (fr)
WO (1) WO2020018825A1 (fr)
ZA (1) ZA202100107B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL314189A (en) 2018-08-01 2024-09-01 Immunitybio Inc A QUADRICISTRONIC SYSTEM COMPRISING A HOMING RECEPTOR OR A CYTOKINE, AND CHIMERIC ANTIGEN RECEPTOR FOR GENETIC MODIFICATION OF IMMUNOTHERAPIES- Expedited Examination
JP7458382B2 (ja) 2018-09-27 2024-03-29 オートラス リミテッド キメラ抗原受容体
US11052112B2 (en) 2019-05-30 2021-07-06 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-BCMA immunotherapy
EP4069373A1 (fr) * 2019-12-06 2022-10-12 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du myélome multiple avec des anticorps bispecifiques anti-bcma x anti-cd3
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
CN115087666B (zh) * 2020-02-13 2023-10-03 北京艺妙神州医药科技有限公司 嵌合抗原受体的优化
EP4136111A1 (fr) * 2020-04-14 2023-02-22 Julius-Maximilians-Universität Würzburg Polythérapie d'atra ou autres rétinoïdes avec des agents immunothérapeutiques se liant à bcma
KR102316091B1 (ko) * 2020-06-17 2021-10-25 국립암센터 Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도
CN112812186B (zh) * 2021-02-08 2022-07-29 华道(上海)生物医药有限公司 一种抗b细胞成熟抗原的纳米抗体及其应用
CN113109572A (zh) * 2021-04-01 2021-07-13 苏州才博医学科技有限公司 一种检测自体cart细胞体液性免疫原性的方法
WO2022221844A2 (fr) * 2021-04-13 2022-10-20 WUGEN, Inc. Récepteurs antigéniques chimériques améliorés et leurs utilisations
CN117730145A (zh) * 2021-07-16 2024-03-19 克莱格医学有限公司 嵌合抗原受体
CN115466331B (zh) * 2021-11-18 2023-05-30 合源生物科技(天津)有限公司 靶向bcma的嵌合抗原受体及其应用
CN118696058A (zh) * 2021-12-03 2024-09-24 山东先声生物制药有限公司 抗bcma纳米抗体及其应用
CN113980907B (zh) * 2021-12-24 2022-03-15 山东兴瑞生物科技有限公司 一种抗flt3嵌合抗原受体修饰的t细胞及其在制备治疗aml药物中的应用
KR20250021397A (ko) * 2022-02-09 2025-02-12 하다지트 메디칼 리서치 써비시즈 앤드 디벨롭먼트 리미티드 면역 관련 질환을 표적으로 하는 항-bcma car, 조성물 및 이의 방법
WO2023193662A1 (fr) * 2022-04-03 2023-10-12 上海先博生物科技有限公司 Récepteur antigénique chimérique ciblant bcma, et son application
CN117143248A (zh) * 2022-05-24 2023-12-01 合源康华医药科技(北京)有限公司 靶向bcma-cd19的双特异性嵌合抗原受体及其应用
US20250101122A1 (en) 2023-09-25 2025-03-27 Kelonia Therapeutics, Inc. Antigen binding polypeptides
WO2025072257A1 (fr) * 2023-09-25 2025-04-03 Kelonia Therapeutics, Inc. Compositions pour le traitement du cancer
US12440564B2 (en) 2023-09-25 2025-10-14 Kelonia Therapeutics, Inc. Compositions for treating cancer
TW202540428A (zh) 2024-01-26 2025-10-16 美商雷傑納榮製藥公司 使用漿細胞耗乏劑及／或ｂ細胞耗乏劑遏制宿主抗ａａｖ抗體反應且實現ａａｖ轉導及重複給藥的方法及組成物
WO2025160340A2 (fr) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Immunosuppression combinée pour inhiber une réponse immunitaire et pour permettre une administration et une réadministration d'immunogène
WO2025171388A1 (fr) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Antigènes du cancer modifiés avec des domaines modifiés et procédés et utilisations associés
WO2025171383A2 (fr) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Antigènes du cancer modifiés et procédés et utilisations associés
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
CN118344480A (zh) * 2024-03-19 2024-07-16 浙江康佰裕生物科技有限公司 靶向bcma的单域抗体、嵌合抗原受体及其应用
WO2026006767A1 (fr) 2024-06-28 2026-01-02 Dispatch Biotherapeutics, Inc. Il-9/il-9r attachées et cellules modifiées et procédés associés

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
EP0228458B2 (fr) 1985-07-05 1997-10-22 Whitehead Institute For Biomedical Research Cellules epitheliales exprimant un materiau genetique etranger
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
EP0633318A1 (fr) 1987-09-11 1995-01-11 Whitehead Institute For Biomedical Research Fibroblastes transduits et leurs applications
EP0391960B1 (fr) 1987-12-11 1994-08-17 Whitehead Institute For Biomedical Research Modification genetique de cellules endotheliales
ATE152169T1 (de) 1988-02-05 1997-05-15 Whitehead Biomedical Inst Modifizierte hepatozyten und deren anwendung
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
JP3249516B2 (ja) 1990-10-31 2002-01-21 ソマティクス セラピー コーポレイション 遺伝子治療のためのレトロウイルスのベクター
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1806143B1 (fr) 1999-08-17 2016-06-15 Biogen MA Inc. Récepteur Baff (BCMA), agent immunorégulateur
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2002248184C1 (en) 2000-12-12 2018-01-04 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
DE10206325A1 (de) 2002-02-14 2003-09-04 Medinnova Ges Med Innovationen Ummantelter Mikroorganismus
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
DK2374818T3 (da) 2006-06-02 2013-01-21 Regeneron Pharma Højaffinitetsantistoffer mod human IL-6-receptor
HRP20161194T1 (hr) 2009-03-10 2016-11-04 Biogen Ma Inc. Anti-bcma protutijela
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
MX349057B (es) 2010-11-30 2017-07-07 Chugai Pharmaceutical Co Ltd Agente terapeutico que induce citotoxicidad.
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
AU2012230780B2 (en) 2011-03-23 2016-10-27 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
FI3415531T3 (fi) 2011-05-27 2023-09-07 Glaxo Group Ltd Bcma:aa (cd269/tnfrsf17) sitovia proteiineja
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
DK3473707T3 (da) 2012-05-25 2025-03-17 Cellectis Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
ES2937015T3 (es) 2012-11-01 2023-03-23 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Anticuerpo contra CD269 (BCMA)
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
EP2762497A1 (fr) 2013-02-05 2014-08-06 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
EP2762496A1 (fr) 2013-02-05 2014-08-06 EngMab AG Procédé pour la sélection d'anticorps contre BCMA
EP2953972B1 (fr) 2013-02-05 2020-07-08 EngMab Sàrl Procédé pour la sélection d'anticorps contre bcma
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
US20180112384A1 (en) 2013-12-30 2018-04-26 Craig Rothleitner Drainage treatment system
KR102405492B1 (ko) 2014-04-30 2022-06-03 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬 름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
RU2747457C2 (ru) * 2014-07-24 2021-05-05 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
EP2982692A1 (fr) 2014-08-04 2016-02-10 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
CN107207609B (zh) 2014-11-20 2022-07-19 豪夫迈·罗氏有限公司 共同轻链和使用方法
EP3029068A1 (fr) 2014-12-03 2016-06-08 EngMab AG Anticorps bispécifiques contre du CD3epsilon et BCMA pour utilisation dans le traitement de maladies
MY191537A (en) 2014-12-05 2022-06-30 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
SMT202100221T1 (it) 2014-12-05 2021-07-12 Memorial Sloan Kettering Cancer Center Anticorpi bersaglianti l'antigene di maturazione delle cellule e metodi d'uso
PL3230321T3 (pl) 2014-12-12 2020-03-31 Bluebird Bio, Inc. Chimeryczne receptory antygenowe bcma
PT3283106T (pt) 2015-04-13 2022-02-02 Pfizer Anticorpos terapêuticos e as suas utilizações
KR102208443B1 (ko) 2015-04-13 2021-01-27 화이자 인코포레이티드 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
US10906982B2 (en) 2015-05-15 2021-02-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
PE20180795A1 (es) 2015-08-17 2018-05-09 Janssen Pharmaceutica Nv Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y uso de estos
LT3353212T (lt) 2015-09-23 2021-12-27 Regeneron Pharmaceuticals, Inc. Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
JP6901493B2 (ja) 2015-11-13 2021-07-14 アメリカ合衆国 抗ｂｃｍａポリペプチド及びタンパク質
BR112018011228A2 (pt) 2015-12-01 2019-01-15 Glaxosmithkline Intellectual Property Development Limited tratamentos de combinação e seus usos e métodos
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
PT3411402T (pt) 2016-02-03 2022-02-01 Amgen Inc Construtos de anticorpos biespecíficos engajadores de células t contra bcma e cd3
JP7152309B2 (ja) 2016-02-17 2022-10-12 シージェン インコーポレイテッド 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用
EP3436036A4 (fr) 2016-04-01 2020-03-18 Kite Pharma, Inc. Molécules de liaison à bcma et procédés d'utilisation associés
WO2017211900A1 (fr) 2016-06-07 2017-12-14 Max-Delbrück-Centrum für Molekulare Medizin Récepteur d'antigène chimère et cellules t-car se liant à bcma
WO2018009904A2 (fr) 2016-07-08 2018-01-11 Tumeh Paul C Compositions et méthodes de traitement pour l'immunothérapie du cancer
MX2019002967A (es) 2016-09-14 2019-07-04 Teneobio Inc Anticuerpos de union a cd3.
CN110036032B (zh) 2016-09-23 2023-09-05 瑞泽恩制药公司 抗muc16(粘蛋白16)抗体
WO2018075359A1 (fr) 2016-10-18 2018-04-26 Boger Henry William Transfert d'énergie sans fil destiné à une commande de processus
KR102687833B1 (ko) 2016-11-02 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 다발성 골수종 치료를 위한 bcma 및 cd3에 대응하는 이중 특이적 항체 및 면역학적 약물의 복합용도
WO2018099539A1 (fr) 2016-11-29 2018-06-07 Horst Lindhofer Combinaison d'anticorps multifonctionnels de redirection de lymphocytes (t) avec des modulateurs de point de contrôle immunitaires et leurs utilisations
KR20250016462A (ko) 2016-12-21 2025-02-03 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
EP3572427B1 (fr) 2017-01-23 2025-06-25 CRAGE medical Co., Limited Anticorps ciblant bcma et son utilisation
WO2018145075A1 (fr) 2017-02-06 2018-08-09 Dana-Farber Cancer Institute, Inc. Compositions et méthodes pour augmenter la signalisation de récepteurs médiée par des anticorps
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
AR111773A1 (es) 2017-05-05 2019-08-21 Amgen Inc Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración
US11970540B2 (en) 2017-06-20 2024-04-30 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
CA3070539A1 (fr) 2017-08-01 2019-02-07 Medimmune, Llc Conjugue anticorps monoclonal-medicament dirige contre bcma
EP3689908A4 (fr) 2017-09-29 2021-09-29 Mogam Institute for Biomedical Research Anticorps anti-bcma ayant une affinité élevée pour bcma et composition pharmaceutique pour le traitement du cancer, comprenant celui-ci
PE20201183A1 (es) 2017-10-13 2020-11-03 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso
PL3674328T3 (pl) * 2018-02-01 2024-09-16 Nanjing IASO Biotechnology Co., Ltd. Chimeryczny receptor antygenu (car) wiążący się z bcma i jego zastosowania
WO2019224717A2 (fr) 2018-05-24 2019-11-28 Janssen Biotech, Inc. Anticorps anti-cd3 et leurs utilisations
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
CA3132587A1 (fr) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie

Also Published As

Publication number Publication date
FI4324851T3 (fi) 2025-10-08
PL3823665T3 (pl) 2024-06-03
AU2026200174A1 (en) 2026-01-29
US12150959B2 (en) 2024-11-26
SG11202100221VA (en) 2021-02-25
SI3823665T1 (sl) 2024-03-29
CN112437671B (zh) 2025-02-25
US20240325445A1 (en) 2024-10-03
MD4324851T2 (ro) 2025-12-31
EP3823665A1 (fr) 2021-05-26
DK3823665T5 (da) 2024-08-19
PH12021550036A1 (en) 2021-09-20
CN119954969A (zh) 2025-05-09
KR20210035832A (ko) 2021-04-01
ES3042810T3 (en) 2025-11-24
HRP20251331T1 (hr) 2025-12-05
HUE073567T2 (hu) 2026-01-28
LT3823665T (lt) 2024-02-26
MA65527B1 (fr) 2024-05-31
ZA202100107B (en) 2024-07-31
CA3106612A1 (fr) 2020-01-23
JP2021531004A (ja) 2021-11-18
JP7601998B2 (ja) 2024-12-17
CO2021000334A2 (es) 2021-01-29
EP4324851A3 (fr) 2024-05-15
BR112021000919A2 (pt) 2021-04-27
HUE066474T2 (hu) 2024-08-28
EP3823665B1 (fr) 2024-01-24
US20200023010A1 (en) 2020-01-23
MY207197A (en) 2025-02-05
FI3823665T3 (fi) 2024-03-01
RS67345B1 (sr) 2025-11-28
MD3823665T2 (ro) 2024-05-31
DK3823665T3 (da) 2024-03-04
CN112437671A (zh) 2021-03-02
JP7404335B2 (ja) 2023-12-25
EP4324851B1 (fr) 2025-08-27
CL2021000142A1 (es) 2021-07-02
SMT202500371T1 (it) 2025-11-10
MX2021000532A (es) 2021-04-12
KR102901020B1 (ko) 2025-12-19
ES2973946T3 (es) 2024-06-25
PL4324851T3 (pl) 2026-01-26
JP2024028944A (ja) 2024-03-05
MX2025004599A (es) 2025-05-02
AU2019308290B2 (en) 2025-10-16
EA202190315A1 (ru) 2021-04-16
CL2022003796A1 (es) 2023-07-07
AU2019308290A1 (en) 2021-02-18
IL279979A (en) 2021-03-01
SI4324851T1 (sl) 2025-12-31
RS65384B1 (sr) 2024-04-30
DK4324851T3 (da) 2025-10-06
EP4324851A2 (fr) 2024-02-21
MX2025004598A (es) 2025-05-02
PT4324851T (pt) 2025-09-23
HRP20240494T1 (hr) 2024-07-05
SMT202400102T1 (it) 2024-05-14
PT3823665T (pt) 2024-02-26
LT4324851T (lt) 2025-10-10
WO2020018825A1 (fr) 2020-01-23

Similar Documents

Publication Publication Date Title
MX2025004598A (es) Receptores antigenicos quimericos con especificidad para bcma y usos de estos
MX2025005515A (es) Anticuerpos anti-bcma x anti-cd3 biespecificos y usos de estos
MX2020013804A (es) Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos.
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
MY200590A (en) Compounds useful as kinase inhibitors
MY208537A (en) Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
PH12022550102A1 (en) Chimeric antigen receptors with mage-a4 specificity and uses thereof
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
AU2018275359A1 (en) Antibodies specific for FLT3 and their uses
MY195059A (en) Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
PH12019502637A1 (en) Chimeric antigen receptors targeting flt3
JOP20160154B1 (ar) أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
EP4589014A3 (fr) Procédés d'immunothérapie pour des patients dont les tumeurs présentent une charge de mutation de gène passager élevée
WO2020014473A8 (fr) INHIBITEURS DE TGFβ1 ET LEUR UTILISATION
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
PH12018500736A1 (en) Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
MX2023014187A (es) Un inhibidor de receptor de interleucina-4 para usarse en el tratamiento de la dermatitis atopica severa.
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
WO2022115565A3 (fr) Récepteurs chimériques et leurs méthodes d'utilisation
WO2020186111A3 (fr) Anticorps se liant à vista et leurs utilisations
EP4257195A3 (fr) Anticorps anti-cfae et méthodes d'utilisation